医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PharmaJet Presents How to Improve Vaccine Performance with Needle-free Delivery at Vaccine World Asia Congress

2021年11月15日 PM11:10
このエントリーをはてなブックマークに追加


 

GOLDEN, Colo.

PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17. The presentation, entitled Improving Vaccine Performance with Needle-free Delivery, is being presented by Paul LaBarre, MS, MBA, Vice President, Global Business Development. The presentation will include collaborative data about needle-free delivery of novel vaccines against polio, rabies, and COVID-19 that demonstrates how PharmaJet’s technology can be used to improve vaccine efficacy, increase campaign coverage, and elevate the patient and caregiver experience.

Recently, the World’s First DNA vaccine for Human Use developed by Zydus Cadila (ZyCoV-D) received Emergency Use Authorization in India for individuals 12 years and above. The vaccine will be delivered exclusively with the PharmaJet Tropis® Intradermal Needle-free Injection System. Samir Desai, President & Head of BU Biologics, of Cadila Healthcare (Zydus Cadila), India will present a Progress Update of the Vaccine Candidate Development – ZyCoV-D, immediately before the PharmaJet presentation. “With a customer-centric approach to healthcare, we at Zydus, have always looked at solutions that provide access to novel concepts and ease of convenience. We are happy to partner with PharmaJet in providing the needle-free application of ZyCoV-D for COVID-19. This first-of-its-kind experience will be a precursor to many more painless vaccinations in the future, bringing about a paradigm shift in preventive care”, said Dr. Sharvil Patel, Managing Director, Zydus Group.

“We are proud to be part of the development and commercialization of the injectable products presented at this conference including ZyCoV-D, the first plasmid-based DNA vaccine. There is a clear and growing body of evidence that needle-free delivery can make injectables better,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc. “Our worldwide partner list is growing quickly, and feedback has been very positive. Our products result in a 90%+ user preference and an 18% increase in vaccination coverage.” 1

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Data on file

About PharmaJet

PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The innovative Stratis® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016. The PharmaJet Needle-free Injectors are safe, fast and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com. Follow us on LinkedIn.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs over 23,000 people worldwide, including 1400 scientists engaged in R & D, and is dedicated to creating healthier communities globally. www.zyduscadila.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005064/en/

CONTACT

Nancy Lillie

Nancy.Lillie@pharmajet.com

1-888-900-4321 Option 3

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917
  • MTTI Receives Chinese Patent for EVATHERA Technology
  • Impella RP Flex with SmartAssistによる治療を世界で初めて実施
  • MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
  • ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia